[go: up one dir, main page]

WO2014119634A1 - Agent de formation musculaire et composition pharmaceutique le contenant - Google Patents

Agent de formation musculaire et composition pharmaceutique le contenant Download PDF

Info

Publication number
WO2014119634A1
WO2014119634A1 PCT/JP2014/052016 JP2014052016W WO2014119634A1 WO 2014119634 A1 WO2014119634 A1 WO 2014119634A1 JP 2014052016 W JP2014052016 W JP 2014052016W WO 2014119634 A1 WO2014119634 A1 WO 2014119634A1
Authority
WO
WIPO (PCT)
Prior art keywords
muscle
atp
utp
increasing agent
atrophy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2014/052016
Other languages
English (en)
Japanese (ja)
Inventor
武田　伸一
尚基 伊藤
友子 鈴木
ウルス ルーグ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Center of Neurology and Psychiatry
Original Assignee
National Center of Neurology and Psychiatry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Center of Neurology and Psychiatry filed Critical National Center of Neurology and Psychiatry
Priority to JP2014559725A priority Critical patent/JPWO2014119634A1/ja
Publication of WO2014119634A1 publication Critical patent/WO2014119634A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a muscle increasing agent and a pharmaceutical composition for treating or preventing a disorder or disease associated with muscle atrophy.
  • the present invention also relates to a method for separating a muscle growth factor.
  • Non-patent Document 1 Skeletal muscle weight is controlled by the balance between protein synthesis and degradation (Non-patent Document 1).
  • muscle protein content decreases due to inhibition of protein synthesis and promotion of protein degradation, resulting in a decrease in muscle mass and atrophy of muscles (disused muscles atrophy).
  • Such muscle atrophy is not only immobilized by space flight under microgravity (Non-patent Document 2), tail suspension (Non-patent Document 3), etc., but also cachexia (Non-patent Document 4), aging (Sarcope) (Non-patent document 5), steroid administration (Non-patent document 6), etc.
  • Non-patent Document 7 amyotrophic lateral sclerosis
  • Non-patent Document 8 muscular dystrophy
  • the method of activating protein synthesis to induce muscle hypertrophy has promise as a treatment for muscle atrophy.
  • the method of activating protein synthesis by general exercise therapy is very difficult for patients with severe muscle atrophy and bedridden elderly people. Therefore, a treatment method that induces muscle atrophy reduction or muscle hypertrophy with drugs without exercise is desired.
  • Non-Patent Document 9 discloses a method of activating protein synthesis by administering Igf-1 that activates the PI3K / Akt pathway.
  • Igf-1 has a risk of promoting myocardial hypertrophy and cancer cell growth.
  • nNOS neuronal nitric oxide synthase
  • TRP Transient receptor potential
  • Non-Patent Document 10 and Patent Documents 1 and 2 are all based on activation of mTOR by controlling intracellular calcium ion concentration via TRPV1. If mTOR can be activated in the same manner as TRPV1 by controlling intracellular calcium ion concentration through other calcium ion channels, muscle atrophy treatment using substances other than TRPV1 agonists becomes possible. In addition, an additive or synergistic effect can be expected in the treatment of muscle atrophy by using such a substance in combination with a TRPV1 agonist.
  • the present invention is a search for a new muscle-increasing agent that acts via a calcium ion channel other than TRPV1, development of a pharmaceutical composition for treating or preventing a disorder or disease associated with muscle atrophy, which contains it as an active ingredient, and It is an object of the present invention to develop and provide a new method for isolating muscle growth factors for promoting muscle hypertrophy and treating muscle atrophy.
  • IP3R inositol triphosphate receptor
  • IP3R inositol trisphosphate receptor
  • PLC phospholipaselipC
  • IP3R signaling pathway via the P2Y receptor that functions on the cell membrane and functions as a nucleic acid receptor is known (Ralevic, V. and Burnstock, G., 1998, Pharmacol Rev, 50: 413-492).
  • FIG. 1 For example, in neurons, as shown in FIG.
  • IP3R present on the endoplasmic reticulum membrane is activated by intracellular signal transduction, and calcium ions Is released.
  • IP3R is known to exist on the sarcoplasmic reticulum membrane (Powell JA, et al., 2001, J Cell Sci, 114: 3673-3683), but via the P2Y receptor. The physiological function of the PLC / IP3R signaling pathway has not been elucidated.
  • the present inventors have also demonstrated that, in the soleus and gastrocnemius muscle cells, the PLC / IP3R signaling pathway via the P2Y receptor induces the release of calcium ions from the sarcoplasmic reticulum.
  • the inventors obtained new knowledge that mTOR can be activated and muscle hypertrophy can be promoted, and the present invention has been completed. That is, the present invention provides the following.
  • muscle increasing agent according to (1) or (2), wherein the muscle increasing agent is inositol triphosphate or a salt thereof, an ester thereof or a prodrug thereof.
  • a pharmaceutical composition for treating or preventing a disorder or disease associated with muscle atrophy comprising the muscle increasing agent according to any one of (1) to (5) as an active ingredient.
  • composition according to (6), wherein the disorder accompanied by muscle atrophy is selected from the group consisting of disuse muscle atrophy, cachexia, sarcopair, and muscle atrophy under microgravity.
  • a method for separating a muscle increasing agent comprising: (a) treating a muscle cell with a test substance and / or a test factor; (b) measuring an activity of IP3R in the muscle cell; c) The method comprising the step of isolating a test substance or test factor that increases the activity of IP3R as a muscle increasing agent based on the measurement result of step (b).
  • a muscle increasing agent that acts via IP3 / Ca 2+ signaling can be provided.
  • composition of the present invention it is possible to provide a pharmaceutical composition for treating or preventing a disorder or disease associated with muscle atrophy, which contains a muscle increasing agent other than a TRPV1 agonist as an active ingredient.
  • FIG. 2A The conceptual diagram of a known P2Y / PLC / IP3R signaling pathway is shown. It is a figure which shows the time-dependent change of the C2C12 intracellular calcium ion concentration after various nucleic acid processing. It is the figure which quantified FIG. 2A. *: P ⁇ 0.05; ***: p ⁇ 0.001 (hereinafter the same) It is a figure which shows the relationship between ATP concentration and intracellular calcium ion concentration. It is a figure which shows the relationship between a UTP density
  • FIG. 3A P2Y shows inhibiting elevation of intracellular calcium concentration by ATP or UTP of 2 when the siRNA treatment. It is a figure which shows the raise suppression of the intracellular calcium concentration by ATP or UTP at the time of IP3R inhibitor XeC treatment.
  • FIG. 3 is a Western blot diagram showing activation of mTOR in C2C12 cells by ATP or UTP treatment by phosphorylation of mTOR substrate p70S6K.
  • FIG. 4 is a western blot diagram showing the results of verification using mTOR inhibitor rapamycin that phosphorylation of the substrate p70S6K by ATP or UTP treatment is derived from the activity of mTOR. The following shows the results of verifying the relationship between mTOR activated in C2C12 cells by ATP or UTP treatment and the increase in C2C12 intracellular calcium ion concentration using extracellular calcium chelator EGTA or intracellular calcium chelator BAPTA-AM It is a Western blot diagram.
  • FIG. 4 is a western blot diagram showing activation of mTOR in C2C12 cells by ATP or UTP treatment by phosphorylation of mTOR substrate p70S6K.
  • FIG. 4 is a western blot diagram showing the results of verification using m
  • FIG. 4 is a Western blot diagram showing that the activity of mTOR by ATP or UTP treatment is via the P2Y / PLC pathway using the P2Y receptor inhibitor suramin or the PLC inhibitor U73122.
  • FIG. 2 is a Western blot diagram showing that mTOR activity by ATP or UTP treatment using P2Y 2 siRNA is via the P2Y / PLC pathway.
  • FIG. 3 is a Western blot diagram showing that the activity of mTOR by ATP or UTP treatment using an IP3R inhibitor XeC is mediated by IP3R. It is a Western blot figure which shows that MAPK in C2C12 cell is activated by ATP or UTP treatment.
  • FIG. 4 is a Western blot diagram showing activation of mTOR in single muscle fibers derived from soleus muscle by ATP treatment by phosphorylation of mTOR substrate p70S6K.
  • the 1st mode of the present invention is related with a muscle increasing agent.
  • the present invention will be specifically described.
  • the muscle increasing agent of this embodiment is a substance that acts on muscle cells and induces muscle increase.
  • muscle increase refers to promotion of muscle hypertrophy, suppression of muscle atrophy, increase of muscle strength or maintenance of muscle strength, or a combination thereof.
  • muscle hypertrophy refers to an increase in muscle weight due to an increase in the weight of a single muscle fiber or cross-sectional area associated with an increase in the amount of endogenous protein
  • promotion of muscle hypertrophy refers to an endogenous protein in a single muscle fiber.
  • promoting the increase in the amount it means promoting the increase in the muscle weight due to the increase in the muscle fiber weight or cross-sectional area.
  • muscle atrophy means a state in which the weight or cross-sectional area of a single muscle fiber is partially reduced, accompanied by a decrease in muscle strength
  • “reduction of muscle atrophy” means the weight or cross-sectional area of a single muscle fiber.
  • Muscle strength is a force (muscle tension) for contracting a muscle
  • “increase or maintenance of muscle strength” means that the force is increased or maintained.
  • the muscle-increasing agent of this aspect acts directly or indirectly on the membrane of the sarcoplasmic reticulum by acting from outside or inside the myocyte and directly activates the inositol triphosphate receptor from the sarcoplasmic reticulum. Muscle gain is induced by the release of calcium ions.
  • muscle cell means a cell constituting skeletal muscle. Although it is substantially synonymous with a myofiber, in the present invention, myoblasts before differentiation into myocytes are also included. Muscle cells can be broadly classified into slow muscle cells (slow muscle fibers) and fast muscle cells (fast muscle fibers). Preferred myocytes in the present invention are slow muscle cells.
  • the sarcoplasmic reticulum is a special smooth endoplasmic reticulum that exists in muscle cells and stores calcium ions inside.
  • the inositol triphosphate receptor described later is distributed on the sarcoplasmic reticulum membrane and contributes to the control of calcium ion concentration in muscle cells.
  • IP3R inositol triphosphate receptor
  • IP3 inositol trisphosphate receptor
  • IP3 ligand inositol triphosphate
  • IP3 inositol trisphosphate
  • the target in the present invention is IP3R that exists particularly on the sarcoplasmic reticulum membrane.
  • the muscle increasing agent of the present invention includes a substance that acts from outside the muscle cell and indirectly activates IP3R, and a substance that acts inside the muscle cell and directly or indirectly activates IP3R.
  • Substances that act from outside the muscle cells and indirectly activate IP3R include, for example, binding to receptors present on the muscle cell membrane, and the IP3 / Ca 2+ signaling pathway (PLC / IP3R in the muscle cell).
  • PLC / IP3R IP3 / Ca 2+ signaling pathway
  • the type of receptor is not particularly limited as long as it exists on the muscle cell membrane and can control the downstream IP3 / Ca 2+ signaling pathway.
  • P2Y receptor including P2Y 1 receptor, P2Y 2 receptor, P2Y 4 receptor and P2Y 6 receptor
  • PAR-1 G protein-coupled receptors.
  • P2Y receptor is preferable.
  • the P2Y receptor agonist is not particularly limited as long as it is a substance that activates the P2Y receptor.
  • nucleotides and other natural and artificial low molecular compounds are examples thereof.
  • the P2Y receptor agonist used in the present invention is preferably ATP or UTP, or a derivative having physiological activity equivalent to them, and salts thereof.
  • ATP derivatives include ATPgammaS (ATP ⁇ S: adenosine 5′-0- (3-thiotriphosphate)), 2-MeSATP (2- (methylthio) adenosine-5′-triphosphate) and the like.
  • ATP and / or UTP are particularly preferable because they are also present in the living body and have a low rate of side effects because of a high metabolic rate in the living body.
  • it may be a P2Y receptor agonist such as diquafosol or a salt thereof.
  • two or more different agonists may be used in combination.
  • the ATP or UTP or a derivative thereof, or a salt thereof can be used in combination.
  • substances that act in muscle cells and indirectly activate IP3R include, for example, active signaling factors that positively regulate the IP3 / Ca 2+ signaling pathway in muscle cells, and such Examples thereof include low-molecular compounds, compounds, peptides and the like that activate signal transduction factors.
  • active signaling factors that positively regulate the IP3 / Ca 2+ signaling pathway in muscle cells
  • low-molecular compounds, compounds, peptides and the like that activate signal transduction factors.
  • Examples of the substance that acts in muscle cells and directly activates IP3R include IP3 or a salt thereof, or an ester or a prodrug thereof.
  • Muscle increase by the muscle increasing agent of the present embodiment is caused by the muscle increasing agent directly or indirectly activating IP3R in muscle cells and inducing calcium ion release from the sarcoplasmic reticulum as described above.
  • mTOR and MAPK are activated by an increase in the concentration of calcium ions in muscle cells via IP3R. From the Examples, activation of MAPK enhances the expression of JunB protein (Raffaello, A., et al., 2010, J Cell Biol 191: 101-113) involved in the promotion of muscle hypertrophy and activation of mTOR Has been suggested to promote JunB protein translation.
  • the muscle increasing agent of this embodiment promotes muscle hypertrophy and / or suppresses muscle atrophy by positively controlling the calcium ion concentration in muscle cells via the IP3 / Ca 2+ signaling pathway. It seems to be.
  • muscle hypertrophy can be induced without accompanying exercise by increasing the calcium ion concentration in muscle cells via the IP3 / Ca 2+ signaling pathway.
  • ATP or UTP which is a muscle increasing agent of this embodiment, is also present in cells and has an advantage of having almost no side effects because of its high metabolic rate.
  • a pharmaceutical composition for treating or preventing a disorder or disease associated with muscle atrophy is a pharmaceutical composition for treating or preventing a disorder or disease associated with muscle atrophy (hereinafter referred to simply as “pharmaceutical composition”). ”)”.
  • pharmaceutical composition for treating or preventing a disorder or disease associated with muscle atrophy
  • the pharmaceutical composition of this aspect contains the muscle increasing agent as described in the said 1st aspect as an active ingredient.
  • One pharmaceutical composition of the present invention may contain one or more muscle increasing agents described in the first aspect. Moreover, it can combine with the method effective in inclusion of other well-known muscle increasing agents other than the muscle increasing agent as described in a 1st aspect, or muscle increase. For example, administration of protein which is a nutrient necessary for muscle increase, administration of hormones (growth hormone, etc.) that assimilate the nutrient to muscle, load on muscle (eg, mild exercise, strength training, pressure training), etc. You may combine. Moreover, it can also be included in one pharmaceutical composition in combination with one or two or more muscle increasing agents described in Japanese Patent Application No. 2012-063182.
  • the amount (content) of the muscle increasing agent according to the first aspect to be blended in the pharmaceutical composition of the present aspect is the type of muscle increasing agent included in the pharmaceutical composition and / or its effective amount (dosage or Intake amount), the type of disorder or disease, the dosage form of the drug composition, and the type of carrier or additive to be described later, and may be appropriately determined in consideration of the respective conditions.
  • the “effective amount” is an amount necessary for the muscle augmenting agent to function as an active ingredient in a pharmaceutical composition, and has almost no adverse side effects on the living body to which it is applied. Or the amount which is not given at all. This effective amount may vary depending on various conditions such as subject information, route of administration, and number of doses.
  • the “subject” refers to a living body to which the pharmaceutical composition is applied.
  • humans livestock (cattle, horses, sheep, goats, pigs, chickens, ostriches, etc.), racehorses, pets (dogs, cats, rabbits, etc.), laboratory animals (mouse, rats, guinea pigs, monkeys, etc.) Applicable.
  • it is a human (in this case, particularly called “subject”).
  • the “subject information” is various individual information of the living body to which the drug composition is applied.
  • the subject is suffering from a general health condition, a disease or a disease.
  • the content of the muscle-increasing agent in the pharmaceutical composition of the present invention varies depending on the conditions, but as a specific example of the content of the muscle-increasing agent per dosage unit of the pharmaceutical composition, it is necessary to use other pharmaceuticals in combination. For human adults who do not, 0.01 to 90% by weight, preferably 1 to 50% by weight, based on the total weight.
  • an effective amount of muscle augmentation agent per day for an adult may be administered for about 1 week to about 1 year, preferably about 1 month to about 12 months, once or several times a day.
  • composition of the present invention may contain a pharmaceutically acceptable carrier as required.
  • “Pharmaceutically acceptable carrier” refers to an additive usually used in the field of pharmaceutical technology. Examples thereof include solvents, excipients, binders, disintegrants, fillers, emulsifiers, fluid addition regulators, lubricants, human serum albumin, and the like.
  • the solvent may be, for example, water or any other pharmaceutically acceptable aqueous solution, or a pharmaceutically acceptable organic solvent.
  • aqueous solution include physiological saline, isotonic solutions containing glucose and other adjuvants, phosphate buffers, and sodium acetate buffers.
  • adjuvants include D-sorbitol, D-mannose, D-mannitol, sodium chloride, low concentration nonionic surfactants, polyoxyethylene sorbitan fatty acid esters, and the like.
  • Excipients include, for example, sugars such as monosaccharides, disaccharides, cyclodextrins and polysaccharides, metal salts, citric acid, tartaric acid, glycine, polyethylene glycol, pluronic, kaolin, silicic acid, or combinations thereof. It is done.
  • binder examples include starch paste using plant starch, pectin, xanthan gum, simple syrup, glucose solution, gelatin, tragacanth, methylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, shellac, paraffin, polyvinylpyrrolidone, or combinations thereof. Can be mentioned.
  • disintegrant examples include the starch, lactose, carboxymethyl starch, crosslinked polyvinylpyrrolidone, agar, laminaran powder, sodium bicarbonate, calcium carbonate, alginic acid or sodium alginate, polyoxyethylene sorbitan fatty acid ester, sodium lauryl sulfate, stearin.
  • examples include acid monoglycerides or salts thereof.
  • fillers examples include petrolatum, the sugar and / or calcium phosphate.
  • emulsifiers examples include sorbitan fatty acid esters, glycerin fatty acid esters, sucrose fatty acid esters, and propylene glycol fatty acid esters.
  • Examples of the flow addition regulator and lubricant include silicate, talc, stearate or polyethylene glycol.
  • solubilizers suspending agents, diluents, dispersants, surfactants, soothing agents, stabilizers, absorption promoters, bulking agents, moisturizers that are commonly used in medicine, if necessary , Moisturizers, wetting agents, adsorbents, flavoring agents, disintegration inhibitors, coating agents, colorants, preservatives, preservatives, antioxidants, fragrances, flavoring agents, sweeteners, buffering agents, tonicity agents, etc. Can be included as appropriate.
  • Such a carrier is mainly used for facilitating the formation of the dosage form and maintaining the dosage form and the drug effect, and for making the muscle-increasing agent, which is an active ingredient, less susceptible to degradation by in vivo enzymes and the like. Therefore, it may be used as needed.
  • the dosage form of the pharmaceutical composition of the present embodiment does not inactivate the muscle increasing agent or other additional active ingredient described in the first aspect which is an active ingredient, and the active ingredient is administered in vivo after administration.
  • the form is not particularly limited as long as it can exert a pharmacological effect.
  • the dosage form of the pharmaceutical composition varies depending on the administration method and / or prescription conditions. In general, the administration methods can be broadly classified into oral administration and parenteral administration, but the pharmaceutical composition may be in a dosage form suitable for each administration method.
  • dosage forms suitable for oral administration include solid preparations (including tablets, pills, sublingual tablets, capsules, drops, lozenges), granules, powders, powders, liquids (internal solutions, suspensions).
  • the solid preparation can be made into a dosage form with a coating known in the art, for example, a sugar-coated tablet, a gelatin-encapsulated tablet, an enteric tablet, a film-coated tablet, a double tablet, or a multilayer tablet as necessary.
  • a coating known in the art, for example, a sugar-coated tablet, a gelatin-encapsulated tablet, an enteric tablet, a film-coated tablet, a double tablet, or a multilayer tablet as necessary.
  • Parenteral administration is subdivided into systemic administration and topical administration, and local administration is further subdivided into tissue administration, transepidermal administration, transmucosal administration, and rectal administration.
  • a suitable dosage form may be used.
  • a dosage form suitable for systemic or intra-tissue administration includes an injection that is a liquid.
  • Suitable dosage forms for transepidermal or transmucosal administration include solutions (including coating agents, eye drops, nasal drops, and inhalants), suspensions (including emulsions and creams), and powders (nasal drops). And a paste agent, a gel agent, an ointment, a plaster, and the like. Suppositories can be mentioned as dosage forms suitable for rectal administration.
  • the administration method is not limited, but local administration directly administered to the target skeletal muscle or systemic administration via the circulatory system can be preferably used.
  • intravascular administration such as intravascular injection (including intravenous injection and intraarterial injection) or lymphatic vessel injection may be mentioned.
  • injectables are combined with the above-mentioned excipients, emulsifiers, suspensions, surfactants, stabilizers, pH adjusters, etc. as appropriate, and mixed in unit dosage forms generally required for pharmaceutical practice. It can be formulated and is provided in unit dose ampoules or multi-dose containers.
  • each dosage form are not particularly limited as long as the dosage form is within the range of dosage forms known in the art for each dosage form.
  • the disorder or disease targeted for treatment or prevention of the pharmaceutical composition of this embodiment is a disorder or disease associated with muscle atrophy.
  • treatment refers to alleviating or eliminating a disorder or disease affected and / or symptoms associated therewith.
  • prevention means prevention of occurrence of a disorder or morbidity of a disease.
  • Disorders associated with muscle atrophy include, for example, disuse muscle atrophy caused by muscle inactivity such as cast fixation and bed rest, malignant tumors, chronic diseases such as respiratory disease, aging (sarcope), and steroid administration Examples include side effects and muscle atrophy under microgravity such as life in outer space.
  • Examples of the disease accompanied by muscular atrophy include amyotrophic lateral sclerosis, muscular dystrophy, and polymyositis.
  • the pharmaceutical composition of the present aspect contains the muscle increasing agent according to the first aspect as an active ingredient, the muscle strength can be maintained by suppressing the progression of muscle atrophy without exercising and / or the muscle strength can be recovered or strengthened by muscle hypertrophy. Can be augmented. Therefore, it can be a useful therapeutic agent for patients with severe muscle atrophy and those who are difficult to exercise such as rehabilitation such as bedridden elderly people.
  • the 3rd aspect of this invention is related with the food-drinks for muscle increase which added the muscle increasing agent of a 1st aspect.
  • the present invention will be specifically described.
  • a food and drink for increasing muscle refers to foods and beverages intended to increase muscle.
  • “food and drink” refers to natural products containing one or more nutrients and processed products thereof, and includes health functional foods such as foods for specified health use and nutritional functional foods, and health foods. Further, not only general foods that humans eat, but also all foods and drinks including feeds fed to animals other than humans such as domestic animals, competing horses, pets, and experimental animals are included.
  • blends the muscle increasing agent as described in a 1st aspect 1 type, or 2 or more types.
  • the blending amount of the muscle increasing agent according to the first aspect in the muscle increasing food or drink is such that the content of the muscle increasing agent according to the first aspect is 0.01 to 90% by weight, for example, with respect to the total amount of the muscle increasing food or drink. What is necessary is just to mix
  • the intake that can be expected to be effective is appropriately determined according to the individual case in consideration of age, weight, gender, symptom level, and the like.
  • the number of intakes can be divided into several times a day, in which case the amount can be divided according to the number of times. In addition, since it has no or little side effects, it can be taken continuously over a long period of time.
  • solid foods include dough for bread, baked confectionery (rice crackers, biscuits, cookies, etc.), noodles, fish products (kamaboko, chikuwa, etc.), livestock products (ham, sausages, etc.), powdered milk, pet food, fodder Etc.
  • jelly-like food examples include fruit jelly and coffee jelly.
  • liquid foods include tea, coffee, tea, soft drinks, fruit drinks, milk drinks, seasonings (mayonnaise, dressings, seasoning liquids, etc.).
  • capsule foods include hard capsules and soft capsules.
  • the food and drink for muscle increase of this aspect is not only a patient having a disorder or disease accompanied by muscle atrophy, but also a healthy individual, as a health supplement product for daily muscle increase if it is a human, Moreover, if it is livestock for meat, it is useful for the purpose of early growth and early shipment.
  • a method for separating muscle gain factors The fourth aspect of the present invention relates to a method for separating muscle gain factors. As shown in the examples described below, activating the IP3 / Ca 2+ signaling pathway via activation of IP3R in muscle cells pharmacologically induces muscle hypertrophy or reduces muscle atrophy. Is possible. Therefore, according to the separation method of the present invention, it is possible to isolate a novel muscle-increasing factor that brings about a pharmacological effect of muscle increase, based on the activation of IP3R in muscle cells by treatment with a test substance.
  • the “muscle increase factor” is a generic term for various factors that can cause muscle increase.
  • the muscle increasing factor includes substances having a muscle increasing action (muscle increasing agent) and environmental factors having a muscle increasing action such as radiation, ultraviolet rays, carbon concentration, temperature, pressure, vibration and the like.
  • the method for separating a muscle growth factor of this embodiment includes (1) a test substance treatment step, (2) an IP3R activity measurement step, and (3) a muscle growth factor separation step as essential steps.
  • the steps from (1) the test substance treatment step to (3) the muscle augmentation factor separation step can be repeated a plurality of times as necessary.
  • an in vivo confirmation step may be included as a selection step after the muscle augmentation factor separation step.
  • test substance etc. treatment step is a step of treating muscle cells expressing IP3R with a test substance and / or a test factor.
  • the type of “myocyte expressing IP3R” used in this step is not particularly limited as long as it is a myocyte expressing IP3R on the sarcoplasmic reticulum membrane.
  • Slow muscle cells are preferred. Any of established myocytes, primary cultured myocytes, subcultured myocytes, etc. may be used. Such muscle cells can be obtained and prepared according to methods known in the art, or commercially available cell lines or publicly available cells can be used. For example, C2C12 (RCB0987, RIKEN BioResource Center cell bank: myoblast cell line), HEK-293 cells (known to overexpress human TRPV1), and the like can be used.
  • test substance refers to a substance that is used in the method for separating muscle augmentation factors of this embodiment and is a candidate substance that is expected as a muscle augmentation factor, that is, a muscle augmentation agent candidate substance.
  • test substance used in this step is not particularly limited.
  • natural substances or non-natural substances can be mentioned.
  • the “natural substance” referred to here is a substance that exists in nature. Examples of the present invention include amino acids, peptides, oligopeptides, polypeptides, proteins, nucleic acids, lipids, carbohydrates (such as sugars), steroids, glycopeptides, glycoproteins, proteoglycans, and the like.
  • Non-natural substances are substances that do not exist in nature and are artificially synthesized.
  • test substance may be a complex composed of a plurality of substances in addition to one composed of a single molecule.
  • the test substance not only a single substance but also two or more different substances can be used in combination.
  • it may be a test substance library composed of a plurality of test substance groups.
  • test substance libraries include synthetic compound libraries (combinatorial libraries, etc.), peptide libraries (combinatorial libraries, etc.) and the like.
  • test factor refers to an environmental factor that can affect muscle cells.
  • radiation ultraviolet rays, carbon concentration, temperature, pressure, vibration and the like can be mentioned.
  • the method of treating muscle cells with a test substance and / or test factor varies depending on the substance or factor.
  • a test substance is usually treated so as to come into contact with muscle cells.
  • the contact condition can be determined based on a known technique in the technical field depending on the type of the test substance. For example, a method of culturing myocytes in a medium containing a test substance, a method of immersing myocytes in a solution containing the test substance, and a method of laminating the test substance on the myocytes.
  • it is a test factor, it will normally treat so that a muscle cell may be exposed to a test factor.
  • a method of culturing myocytes in an environment where the test factor is present can be mentioned.
  • Conditions such as the amount (amount, concentration) or strength of the test substance and / or test factor, treatment time, number of times, etc. may be determined as necessary.
  • a plurality of doses can be set by preparing a dilution series of the test substance.
  • the treatment time can also be set as appropriate.
  • the treatment can be performed over a period of one day to several weeks, months, and years.
  • IP3R activity measurement step is a step of measuring the activity of IP3R in the myocytes treated in the test substance treatment step.
  • IP3R activity may be measured at an appropriate time after the test substance treatment step. For example, immediately after the test substance treatment step, 30 minutes, 1 hour, 3 hours, 5 hours, 10 hours, 15 hours, 20 hours, 24 hours (1 day), 2-10 days Measure after 10-20 days, after 20-30 days, and after 1-6 months.
  • IP3R activation can be measured by methods known in the art. For example, a method of measuring by a change in calcium ion concentration in muscle cells or a change in calcium ion concentration in sarcoplasmic reticulum can be mentioned. As a specific method, for example, by measuring the fluorescence intensity in muscle cells using Fluo-4 that emits fluorescence by binding to calcium ions, the calcium ion concentration in muscle cells is measured. (Gee KR, et al., Cell Calcium. 2000, 27 (2): 97-106).
  • IP3R activity in muscle cells before treatment with the test substance and / or test factor or for a control cultured under the same conditions and not treated with the test substance and / or test factor It is desirable to measure the IP3R activity of myocytes as a control activity.
  • the measurement method of the control activity is the same as the measurement method performed on the myocytes treated in the test substance treatment step, except that the myocytes are not treated with the test substance and / or test factor. That's fine.
  • Muscle increase factor separation step refers to a test substance and / or test factor that increases IP3R activity based on the measurement result in the IP3R activity measurement step. As a step to separate.
  • the increase in IP3R activity is determined by the measurement result in the IP3R activity measurement step.
  • the determination can be made based on, for example, a statistically significant difference from the control. Specifically, when the IP3R activity (measurement activity) in the myocytes treated with the test substance and / or the test factor is compared with the control activity, the measurement activity increases statistically significantly with respect to the control activity. If so, it may be determined that the activity of IP3R has increased.
  • “statistically significant” means that there is a significant difference when the measured activity and the control activity are treated statistically. Specifically, for example, the risk rate (significance level) is less than 5%, 1%, or 0.1%.
  • the test method is not particularly limited as long as it is a known method capable of determining the presence or absence of significance. For example, a student-t test method or a multiple comparison test method can be used.
  • the determination can be performed based on the measurement threshold value. Specifically, if the measured activity is equal to or greater than a predetermined threshold, it may be determined that the activity of IP3R has increased.
  • the test substance or test factor used for the treatment of muscle cells in the test substance treatment step is separated as a muscle increase factor.
  • the test substance or test factor used in the test substance treatment step is a single substance or a single environmental factor, the substance or environmental factor can be recognized as a muscle increasing factor.
  • the test substances and / or test factors separated in this step are , Isolated as a muscle growth factor candidate including at least one muscle growth factor.
  • the first series of steps in the separation method of the present aspect is a primary separation process, and the test substance or test factor obtained by separating or subtracting a part of the test substance or test factor used in the test substance treatment step of the primary separation process Using the (secondary test substance or the like), a series of steps in the separation method of this embodiment is executed again as a secondary separation step. If it is determined that the IP3R activity has increased in the secondary separation step, the target muscle growth factor is included in the secondary test substance or the like. In this way, when the muscle cells are treated with a combination of two or more different substances or test substances and test factors in the test substance treatment step, the secondary separation step and subsequent steps are repeated as necessary to increase muscle growth factors. By gradually narrowing down the candidates, the target muscle increasing factor can be obtained.
  • the “in vivo confirmation step” means that an animal is treated with a muscle augmentation factor or a muscle augmentation factor candidate separated at a muscle augmentation factor separation step, and IP3R activation or muscle in vivo. This is a step to confirm the increase. This step is a selection step performed after the muscle increase factor separation step, and may be performed as necessary for the purpose of separating a highly effective muscle increase factor.
  • a laboratory animal may be used.
  • a model animal preferably a mouse, in which muscle atrophy has been induced by hindlimb suspension, denervation, dexamethasone administration, or the like can be used.
  • the muscle growth factor or the muscle growth factor candidate separated in the muscle growth factor separation step is administered to the animal, the activation of IP3R in the muscle cells of the animal is measured, and whether or not the muscle gain has increased in the animal. Can be determined. Whether or not a muscle growth factor or a muscle growth factor candidate has a muscle increasing action in an animal can be appropriately determined by a method known in the art, although it varies depending on the type of animal. For example, after a muscle growth factor or muscle growth factor candidate is administered to an experimental animal, muscle tissue is collected from the animal, and muscle weight, muscle cross-sectional area, muscle tension, etc. are measured to confirm the muscle increasing effect. be able to.
  • a new muscle growth factor having a pharmacological effect of muscle growth that induces muscle hypertrophy or reduces muscle atrophy via IP3 / Ca 2+ signaling pathway in muscle cells is isolated. can do.
  • C2C12 cells a mouse myoblast cell line
  • Nucleic acids used as ligands are ATP, UTP, TTP, CTP, GTP, ATP ⁇ S, 2-MeS ATP, ADP, AMP and adenosine (all Sigma-Aldrich).
  • 2 ⁇ M thapsigargin (tg) (Calbiochem) was used as a calcium depleting agent for sarcoplasmic reticulum.
  • C2C12 myotube was treated with various nucleic acids, and intracellular calcium ion concentration was monitored using calcium indicator Fluo-4.
  • the concentration of each nucleic acid was treated with 100 ⁇ M.
  • the experiment in which the concentration was varied was performed at 0.1, 1, 10, 100, or 1000 ⁇ M (according to the illustrated concentration).
  • the following method was used for measurement of intracellular calcium ion concentration.
  • C2C12 cells were cultured in growth medium (DMEM, 10% fetal bovine serum, 1% penicillin-streptomycin) at 37 ° C. under 5% CO 2 , and then differentiation medium (DMEM, 2% horse serum, 1 % Penicillin-streptomycin) for 2 days to induce muscle differentiation.
  • DMEM 10% fetal bovine serum, 1% penicillin-streptomycin
  • C2C12 cells in which myogenic differentiation was induced were cultured in serum-free DMEM for 8 hours, and then PSS solution (140 mM NaCl, 5 mM KCl, 2.5 mM CaCl 2 , 1 mM MgCl 2 , 10 mM HEPES, 10 After culturing for 6 hours or more in mM glucose, pH 7.0), a calcium indicator Fluo-4 (DOJINDO) (4 ⁇ M) was added and incubated at room temperature for 30 minutes. After removing excess Fluo-4 and culturing at 37 ° C. for 5 minutes, changes in fluorescence intensity due to treatment with each nucleic acid were measured over time using an inverted fluorescence microscope (Olympus) every 180 seconds until 180 seconds later.
  • PSS solution 140 mM NaCl, 5 mM KCl, 2.5 mM CaCl 2 , 1 mM MgCl 2 , 10 mM HEPES, 10
  • DOJINDO calcium indicator Fluo
  • Student-t test was used to compare the data between the two groups. For comparison between multiple groups, ANOVA test was performed and then multiple group test by Tukey's method was performed. Data are shown using the mean value ⁇ standard error, and p ⁇ 0.05 was determined to be significant.
  • FIGS. 2A-F Results are shown in FIGS. 2A-F.
  • FIGS. 2A and 2B among the main nucleic acids ATP, UTP, CTP, TTP, and GTP, it was revealed that the intracellular calcium ion concentration was increased by ATP and UTP. Further, as shown in FIGS. 2C and 2D, it was also found that the intracellular calcium ion concentration increases depending on the concentration of ATP or UTP, but slightly decreases when treated at a high concentration such as 1000 ⁇ M.
  • the increase in intracellular calcium ion concentration by ATP or UTP was suppressed by the addition of a suramin or U73122 inhibitor.
  • the result of suppressing the expression of P2Y 2 by siRNA increase in intracellular calcium ion concentration by ATP or UTP was inhibited.
  • the increase in intracellular calcium ion concentration by ATP or UTP was inhibited by XeC. From these results, it was proved that the intracellular calcium ion concentration was also increased in the skeletal muscle cells by the activation of the P2Y / PLC / IP3R pathway by ATP or UTP.
  • Example 4 (the purpose) In Experimental Example 3, it was verified that the increase in intracellular calcium ion concentration in single muscle fibers due to ATP or UTP was via P2Y receptor, PLC, and IP3R calcium ion channel.
  • the basic material conformed to Experimental Examples 1 to 3.
  • the ligand is ATP
  • the P2Y receptor inhibitor, PLC inhibitor, and IP3R inhibitor are 100 ⁇ M suramin (Sigma-Aldrich), 10 ⁇ M U73122 (Sigma-Aldrich), and 2 ⁇ M xestospongin C (XeC; Sigma-Aldrich) was used.
  • 0Ca 2+ solution 140 mM NaCl, 5 mM KCl, 1 mM MgCl 2 , 10 mM HEPES, 10 mM glucose, 2 mM EGTA, pH 7.0 was used to remove extracellular calcium from single muscle fibers. .
  • FIG. 9 shows the result.
  • the increase in intracellular calcium concentration due to ATP was suppressed by P2Y receptor inhibitor (suramin), PLC inhibitor (U73122), and IP3R inhibitor (XeC).
  • P2Y receptor inhibitor suramin
  • PLC inhibitor U73122
  • IP3R inhibitor XeC
  • removal of extracellular calcium did not inhibit the increase in intracellular calcium concentration by ATP (0Ca 2+ ). From these results, it was demonstrated that the ATP-dependent increase in intracellular calcium concentration observed in single muscle fibers in Experimental Example 3 occurred via the P2Y / PLC / IP3 receptor pathway.
  • Example 1 Activation of mTOR in skeletal muscle cells by P2Y receptor activation
  • Primary antibodies for Western blot include p70S6K antibody (# 9202, Cell Signaling Technology), p-p70S6K (Thr421 / Ser424) antibody (# 9204, Cell Signaling Technology), p-p70S6K (Thr389) antibody (# 9205, Cell Signaling) Technology), Akt antibody (# 9272, Cell Signaling Technology), p-Akt (Ser473) antibody (# 9271, Cell Signaling Technology) and p-Akt (Thr308) antibody (# 9275, Cell Signaling Technology).
  • a rabbit-specific HRP-labeled antibody GE Healthcare
  • 0.1 ⁇ M rapamycin was used as an mTOR inhibitor.
  • 50 ⁇ M BAPTA-AM Calbiochem
  • 2 mM EGTA Sigma-Aldrich
  • the Western blot was performed according to the following procedure. First, C2C12 cells were sample buffer (0.1% Triton X-100, 50 mM HEPES (pH 7.4), 4 mM EGTA, 10 mM EDTA, 15 mM Na 4 P 2 O 7 , 100 mM glycerophosphate, 25 mM NaF, 5 mM Homogenized with Na 2 VO 4 and complete protease inhibitor cocktail (Roche) and centrifuged (15,000 g, 10 minutes) and the supernatant was collected.
  • C2C12 cells were sample buffer (0.1% Triton X-100, 50 mM HEPES (pH 7.4), 4 mM EGTA, 10 mM EDTA, 15 mM Na 4 P 2 O 7 , 100 mM glycerophosphate, 25 mM NaF, 5 mM Homogenized with Na 2 VO 4 and complete protease inhibitor cocktail (Roche) and centrifuged
  • sample loading buffer (30% glycerol, 5% 2-mercaptoethanol, 2.3% SDS, 62.5 mM Tris-HCl (pH 6.8)) , 0.05% bromophenol blue
  • sample loading buffer 30% glycerol, 5% 2-mercaptoethanol, 2.3% SDS, 62.5 mM Tris-HCl (pH 6.8)) , 0.05% bromophenol blue
  • heat-denatured at 60 ° C. for 15 minutes. 30 ⁇ g was subjected to Western blot.
  • the PVDF transfer membrane was blocked with Tris-buffered saline (TBS) + 5% skim milk (snow mark), and incubated for 16 hours at 4 ° C. using the primary antibody.
  • the transfer membrane was washed with Tris buffered saline (TBST) containing 0.1% Tween 20, and then incubated with a secondary antibody. It was washed again with TBST and detected with ECL Western Blotting Detection System (GE HealthCare, Buckinghamshire).
  • TBST Tris buffered saline
  • phosphorylation of Thr at position 389 (start Met is position 1; the same applies hereinafter), Thr at position 421, and Ser at position 424, in p70S6K, which is a mTOR substrate, by ATP or UTP treatment. It rose in a concentration-dependent manner.
  • phosphorylation of p70S6K by ATP or UTP was inhibited by rapamycin, an mTOR inhibitor. From these results, it became clear that mTOR is also activated by ATP or UTP in skeletal muscle cells.
  • Example 2 Activation of MAPK by P2Y activation and regulation of expression of downstream gene JunB
  • MAPK is activated by an increase in intracellular calcium ion concentration and is involved in various downstream gene expression regulation (Hazzalin CA & Mahadevan LC, 2002, Nat Rev Mol Cell Biol. 3 (1): 30 -40). Therefore, it is verified whether the increase of calcium ion concentration in muscle cells by ATP / UTP activates various signal molecules such as MAPK other than mTOR, and if MAPK is activated, downstream genes are expressed. did.
  • Primary antibodies for Western blot include p-Erk1 / 2 (Thr202 / Tyr204) antibody (# 9101, Cell Signaling Technology) for p44 / 42 MAPK, and p-AMPK ⁇ (Thr172) antibody (# 2535, Cell Signaling for AMPK ⁇ Technology) and AMPK ⁇ antibody (# 2603, Cell Signaling Technology) and JunB antibody (sc-46, Santa Cruz) were used.
  • p-Erk1 / 2 (Thr202 / Tyr204) antibody # 9101, Cell Signaling Technology) for p44 / 42 MAPK
  • p-AMPK ⁇ (Thr172) antibody # 2535, Cell Signaling for AMPK ⁇ Technology
  • AMPK ⁇ antibody # 2603, Cell Signaling Technology
  • JunB antibody JunB antibody
  • the treadmill (MK-680S, Muromachi Kikai) was used for the exercise load to the mouse. After running at an initial speed of 5 m / min for 5 minutes, the speed was increased by 1 m / min every minute and increased to a speed of 20 m / min. After running for a total of 30 minutes, the gastrocnemius muscle was excised and collected under anesthesia (Moresi, V. et al., 2010, Cell 143, 35-45). Control group mice underwent sham surgery to cut the skin.
  • phosphorylation of Thr at position 202 and Thr at position 204 in p-Erk1 / 2 increased in a concentration-dependent manner by ATP or UTP treatment. From this result, it became clear that MAPK is activated by ATP or UTP also in skeletal muscle cells. On the other hand, no concentration-dependent increase in phosphorylation of AMPK was observed.
  • Example 3 Promotion of muscle hypertrophy by administration of ATP or UTP] (the purpose) It was confirmed that muscle hypertrophy was promoted by administering ATP or UTP, which is a muscle increasing agent of the present invention, to mice in which disuse muscle atrophy was induced.
  • rapamycin 10 ⁇ M rapamycin (Sigma-Aldrich) was used as an mTOR inhibitor, and 50 ⁇ M BAPTA-AM (Calbiochem) was used as an intracellular calcium chelator.
  • mice Disuse muscle atrophy in mice was induced by hindlimb suspension (Suzuki, N. et al., 2007, J Clin Invest 117, 2468-2476). Specifically, the mice were reared so that their hind limbs were separated from the floor by 1 mm or more. Two weeks later, the gastrocnemius and soleus were extracted from the mouse, and the body weight and muscle weight were measured. In addition, the gastrocnemius muscle is a muscle having a higher proportion of slow muscles than other skeletal muscles, like the soleus muscle.
  • mice neurogenic muscle atrophy in mice was induced by sciatic nerve resection (Moresi, V. et al., 2010, Cell, 143: 35-45). Two weeks after excision of the sciatic nerve, the gastrocnemius and soleus were removed from the mouse, and the muscle weight was measured.
  • mice were excised under anesthesia (Adams, G. R. & Haddad, F., J Appl Physiol, 1996, 81: 2509-2516).
  • the control group received a sham operation to cut the skin.
  • the muscle weights of the soleus muscle (FIGS. 6A and 6C) and gastrocnemius muscle (FIG. 6B) were increased by administration of ATP or UTP. This increase in muscle weight by ATP was suppressed by BAPTA-AM or rapamycin (FIGS. 6A, B, and C).
  • FIG. 6D shows the therapeutic effect of ATP or UTP on soleus muscle atrophy caused by unloading
  • FIG. 6E shows the therapeutic effect of ATP or UTP on gastrocnemius muscle atrophy caused by denervation.
  • muscle atrophy was induced in the control group to which ATP or UTP was not administered, but the decrease in muscle weight was attenuated in the ATP or UTP administration group.
  • the muscle increasing agent of the present invention such as ATP or UTP can be administered to muscle cells to control intracellular calcium ion concentration via the P2Y / PLC / IP3R signaling pathway. It has been proved that mTOR and MAPK can be activated by this, and muscle hypertrophy can be promoted and muscle atrophy can be reduced by the expression of JunB protein.
  • the reagents and the like basically used those described in Example 1. Specifically, p70S6K antibody (# 9202, Cell Signaling Technology), p-p70S6K (Thr421 / Ser424) antibody (# 9204, Cell Signaling Technology), p-p70S6K (Thr389) antibody (# 9205, Cell Signaling Technology) and Akt antibody (# 9272, Cell Signaling Technology).
  • p70S6K antibody # 9202, Cell Signaling Technology
  • p-p70S6K (Thr421 / Ser424) antibody # 9204, Cell Signaling Technology
  • p-p70S6K (Thr389) antibody # 9205, Cell Signaling Technology
  • Akt antibody # 9272, Cell Signaling Technology
  • ATP was used as the ligand.
  • ATP was administered to mice by intramuscular injection according to the method described in Example 3. Isolation of soleus muscle-derived single muscle fibers from ATP-administered mice followed the method described in Experimental Example 3. Other basic operations were performed according to Example 1.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne le développement et la production d'un nouvel agent de formation musculaire dont les principes actifs sont un promoteur d'hypertrophie musculaire et un agent thérapeutique contre l'atrophie musculaire, qui peut induire une formation musculaire sans exercice, et qui a peu d'effets secondaires. L'invention porte, par exemple, sur un agent de formation musculaire qui contient un antagoniste des récepteurs P2Y tels que APT et UTP, et qui active directement ou indirectement les récepteurs de l'inisitol trisphosphate dans la membrane du réticulum sarcoplasmique, induisant ainsi la libération d'ions calcium à partir du réticulum sarcoplasmique.
PCT/JP2014/052016 2013-01-30 2014-01-30 Agent de formation musculaire et composition pharmaceutique le contenant Ceased WO2014119634A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2014559725A JPWO2014119634A1 (ja) 2013-01-30 2014-01-30 筋増加剤及びそれを含む医薬組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013015927 2013-01-30
JP2013-015927 2013-01-30

Publications (1)

Publication Number Publication Date
WO2014119634A1 true WO2014119634A1 (fr) 2014-08-07

Family

ID=51262346

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2014/052016 Ceased WO2014119634A1 (fr) 2013-01-30 2014-01-30 Agent de formation musculaire et composition pharmaceutique le contenant

Country Status (2)

Country Link
JP (1) JPWO2014119634A1 (fr)
WO (1) WO2014119634A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005084440A1 (fr) * 2004-03-02 2005-09-15 Technical Sourcing International, Inc. Methode pouvant augmenter la masse musculaire et la force par administration d'adenosine triphosphate
WO2007044411A2 (fr) * 2005-10-06 2007-04-19 Eli Lilly And Company Anticorps anti-myostatine
WO2007047112A2 (fr) * 2005-10-12 2007-04-26 Eli Lilly And Company Anticorps anti-myostatine
WO2011098449A1 (fr) * 2010-02-10 2011-08-18 Novartis Ag Procédés et composés pour la croissance de muscle

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005084440A1 (fr) * 2004-03-02 2005-09-15 Technical Sourcing International, Inc. Methode pouvant augmenter la masse musculaire et la force par administration d'adenosine triphosphate
WO2007044411A2 (fr) * 2005-10-06 2007-04-19 Eli Lilly And Company Anticorps anti-myostatine
WO2007047112A2 (fr) * 2005-10-12 2007-04-26 Eli Lilly And Company Anticorps anti-myostatine
WO2011098449A1 (fr) * 2010-02-10 2011-08-18 Novartis Ag Procédés et composés pour la croissance de muscle

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
IQBAL, T. R. ET AL.: "Signal transduction pathways of IP3R3-containing microvillous cells", CHEMICAL SENSES, vol. 36, no. 9, 2011, pages A97 - A98 *
KOBIELOWA, Z. ET AL.: "Clinical studies and attempted ATP therapy of progressive muscular dystrophy in children.", NEUROLOGIA, NEUROCHIRURGIA I PSYCHIATRIA POLSKA, vol. 11, no. 6, 1961, pages 803 - 809 *
MASAO NAKAHARA ET AL.: "Zenkecchu ni Okeru ATP, UTP Oyobi ITP no Bunkai ni Tsuite", SOGO IGAKU, vol. 20, no. 9, 1963, pages 679 - 682 *
MASAO NAKAHARA: "Shinkosei dystrophy no ATP Ryoho", SEIKEI GEKA, vol. 16, no. 4, 1965, pages 299 - 318 *
NAKAHARA, M.: "Progressive muscular dystrophy. I. Effects of adenosine triphosphate and its related compounds on progressive muscular dystrophy", ARZNEIMITTEL-FORSCHUNG, vol. 15, no. 6, 1965, pages 591 - 595 *
ORELLANA, J. A. ET AL.: "Glucose increases intracellular free Ca2+ in tanycytes via ATP released through connexin 43 hemichannels", GLIA, vol. 60, no. 1, 2012, pages 53 - 68 *
RYTEN, M. ET AL.: "Purinoceptor expression in regenerating skeletal muscle in the mdx mouse model of muscular dystrophy and in satellite cell cultures", FASEB JOURNAL, vol. 18, no. 10, 2004, Retrieved from the Internet <URL:http://www.fasebj.org/content/early/2004/08/28/fj.03-1175fje.full.pdfl> [retrieved on 20140422] *
STELGENS, P.: "Über die Behandlung der Dystrophia musculorum progressiva (Erb) mit Adenosintriphosphorsaure", DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, vol. 82, no. 41, 1957, pages 1761 - 1763 *

Also Published As

Publication number Publication date
JPWO2014119634A1 (ja) 2017-01-26

Similar Documents

Publication Publication Date Title
Neeland et al. Changes in lean body mass with glucagon‐like peptide‐1‐based therapies and mitigation strategies
Shetty et al. Role of the circadian clock in the metabolic syndrome and nonalcoholic fatty liver disease
Suwa et al. Effects of chronic AICAR treatment on fiber composition, enzyme activity, UCP3, and PGC-1 in rat muscles
Lynch et al. Leucine is a direct-acting nutrient signal that regulates protein synthesis in adipose tissue
US20240301022A1 (en) Glycoproteins having lipid mobilizing properties and therapeutic uses thereof
Bohnert et al. Inhibition of ER stress and unfolding protein response pathways causes skeletal muscle wasting during cancer cachexia
Li et al. Berberine improves pressure overload-induced cardiac hypertrophy and dysfunction through enhanced autophagy
Liu et al. Dysregulations of mitochondrial quality control and autophagic flux at an early age lead to progression of sarcopenia in SAMP8 mice
Ma et al. Caloric restriction can improve learning and memory in C57/BL mice probably via regulation of the AMPK signaling pathway
Gatta et al. Modulating the metabolism by trimetazidine enhances myoblast differentiation and promotes myogenesis in cachectic tumor-bearing c26 mice
Wu et al. Porcupine inhibitor CGX1321 alleviates heart failure with preserved ejection fraction in mice by blocking WNT signaling
Boutry et al. Pulsatile delivery of a leucine supplement during long-term continuous enteral feeding enhances lean growth in term neonatal pigs
Moore et al. Early post-hatch fasting induces satellite cell self-renewal
Mason et al. Metformin in gestational diabetes: physiological actions and clinical applications
Go et al. 6′-sialyllactose prevents dexamethasone-induced muscle atrophy by controlling the muscle protein degradation pathway
WO2014119634A1 (fr) Agent de formation musculaire et composition pharmaceutique le contenant
Konstantynowicz-Nowicka et al. Cannabidiol and sphingolipid metabolism–an unexplored link offering a novel therapeutic approach against high-fat diet-induced hepatic insulin resistance.
Gericke et al. Neuropeptide Y impairs insulin-stimulated translocation of glucose transporter 4 in 3T3-L1 adipocytes through the Y1 receptor
Lu et al. Targeting Dlat-Trpv3 pathway by hyperforin elicits non-canonical promotion of adipose thermogenesis as an effective anti-obesity strategy
WO2013141202A1 (fr) Agent de construction musculaire et procédé de criblage pour une substance de construction musculaire
KR102696915B1 (ko) 고미신 g를 유효성분으로 함유하는 근육위축증 예방, 개선 또는 치료용 조성물
JP2014152149A (ja) Ａｍｐキナーゼ活性化剤及びその用途
EP4663193A1 (fr) Composition pharmaceutique pour la prévention ou le traitement des troubles musculo-squelettiques liés à l&#39;âge
Gu et al. Reduced expression of transmembrane protein 43 during cardiac hypertrophy leading to deteriorating heart failure in mice
Dias et al. What is new in cancer cachexia comprehension and treatment?

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14745702

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2014559725

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14745702

Country of ref document: EP

Kind code of ref document: A1